IPHA vs. OPT, INMB, ABOS, CMPX, ZURA, IPSC, AGEN, KOD, FENC, and ELEV
Should you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Opthea (OPT), INmune Bio (INMB), Acumen Pharmaceuticals (ABOS), Compass Therapeutics (CMPX), Zura Bio (ZURA), Century Therapeutics (IPSC), Agenus (AGEN), Kodiak Sciences (KOD), Fennec Pharmaceuticals (FENC), and Elevation Oncology (ELEV). These companies are all part of the "biological products, except diagnostic" industry.
Opthea (NASDAQ:OPT) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, community ranking, institutional ownership, risk, valuation, analyst recommendations and earnings.
Opthea has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.
Innate Pharma has higher revenue and earnings than Opthea.
In the previous week, Innate Pharma had 6 more articles in the media than Opthea. MarketBeat recorded 7 mentions for Innate Pharma and 1 mentions for Opthea. Innate Pharma's average media sentiment score of 1.14 beat Opthea's score of 0.39 indicating that Opthea is being referred to more favorably in the media.
Innate Pharma received 24 more outperform votes than Opthea when rated by MarketBeat users. Likewise, 54.93% of users gave Innate Pharma an outperform vote while only 50.00% of users gave Opthea an outperform vote.
56.0% of Opthea shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 3.2% of Opthea shares are held by insiders. Comparatively, 31.9% of Innate Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Opthea currently has a consensus price target of $14.00, suggesting a potential upside of 310.56%. Innate Pharma has a consensus price target of $9.75, suggesting a potential upside of 259.79%. Given Innate Pharma's higher possible upside, equities research analysts plainly believe Opthea is more favorable than Innate Pharma.
Summary
Opthea and Innate Pharma tied by winning 6 of the 12 factors compared between the two stocks.
Get Innate Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innate Pharma Competitors List
Related Companies and Tools
